• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与伊匹木单抗治疗晚期转移性黑色素瘤相关的大疱性类天疱疮。

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.

作者信息

Hanley T, Papa S, Saha M

机构信息

Department of Dermatology, Queen Elizabeth Hospital, London SE18 4QH, UK.

Cancer Studies, Bermondsey Wing, King's College London, London SE1 9RT, UK.

出版信息

JRSM Open. 2018 Oct 3;9(10):2054270418793029. doi: 10.1177/2054270418793029. eCollection 2018 Oct.

DOI:10.1177/2054270418793029
PMID:30302265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6170966/
Abstract

Immunotherapy is now being routinely used in the management of many cancers. It is therefore vital that all clinicians are aware of the diverse array of cutaneous manifestations that can result from their use, which can vary from mild to life threatening.

摘要

免疫疗法目前正常规用于多种癌症的治疗。因此，所有临床医生都必须了解使用免疫疗法可能导致的各种各样的皮肤表现，这些表现从轻微到危及生命不等。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de90/6170966/1dbb7bb61341/10.1177_2054270418793029-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de90/6170966/afce3b6bbeca/10.1177_2054270418793029-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de90/6170966/1dbb7bb61341/10.1177_2054270418793029-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de90/6170966/afce3b6bbeca/10.1177_2054270418793029-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de90/6170966/1dbb7bb61341/10.1177_2054270418793029-fig2.jpg

相似文献

1
Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.与伊匹木单抗治疗晚期转移性黑色素瘤相关的大疱性类天疱疮。
JRSM Open. 2018 Oct 3;9(10):2054270418793029. doi: 10.1177/2054270418793029. eCollection 2018 Oct.
2
Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.两例与免疫检查点抑制剂相关的大疱性类天疱疮罕见病例。
BMJ Case Rep. 2022 Dec 7;15(12):e253059. doi: 10.1136/bcr-2022-253059.
3
A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.一例继发于检查点抑制剂免疫治疗的大疱性类天疱疮罕见病例：情况危急
Cureus. 2021 Jul 4;13(7):e16169. doi: 10.7759/cureus.16169. eCollection 2021 Jul.
4
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.免疫检查点抑制剂相关的大疱性皮肤免疫相关不良事件：一项多中心观察性研究。
Br J Dermatol. 2022 Dec;187(6):981-987. doi: 10.1111/bjd.21836. Epub 2022 Sep 6.
5
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.老年女性非小细胞肺癌患者应用帕博利珠单抗治疗后发生大疱性类天疱疮：病例报告及文献复习。
J Oncol Pharm Pract. 2021 Apr;27(3):727-733. doi: 10.1177/1078155220946370. Epub 2020 Aug 9.
6
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.一名接受派姆单抗治疗转移性黑色素瘤的患者出现迟发性泛发性类大疱性类天疱疮样反应。
Australas J Dermatol. 2017 Aug;58(3):e109-e112. doi: 10.1111/ajd.12488. Epub 2016 May 11.
7
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.与程序性细胞死亡蛋白1抑制剂治疗相关的皮肤不良反应的发作时间。
JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912.
8
Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.放射性治疗联合纳武利尤单抗治疗肾细胞癌后出现大疱性类天疱疮：一种远隔毒性的病例报告。
Medicine (Baltimore). 2021 Dec 10;100(49):e28199. doi: 10.1097/MD.0000000000028199.
9
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.120例黑色素瘤患者中检查点抑制剂诱发的皮肤表现——欧洲MelSkinTox研究
J Eur Acad Dermatol Venereol. 2023 Apr 12. doi: 10.1111/jdv.19112.
10
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.转移性黑色素瘤患者接受依匹单抗治疗的皮肤不良反应：一项前瞻性研究。
Eur J Dermatol. 2017 Jun 1;27(3):266-270. doi: 10.1684/ejd.2017.3023.

引用本文的文献

1
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.免疫检查点抑制剂相关的皮肤不良事件：发生机制
Int J Mol Sci. 2024 Dec 26;26(1):88. doi: 10.3390/ijms26010088.
2
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂诱导的皮肤免疫相关不良事件（irAEs）的分子机制。
Curr Oncol. 2023 Jul 18;30(7):6805-6819. doi: 10.3390/curroncol30070498.
3
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.

本文引用的文献

1
Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.一名转移性恶性黑色素瘤患者在使用纳武单抗治疗失败后，因使用伊匹单抗诱发大疱性类天疱疮。
J Dermatol. 2018 Jan;45(1):e21-e22. doi: 10.1111/1346-8138.14043. Epub 2017 Sep 25.
2
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.转移性黑色素瘤患者接受依匹单抗治疗的皮肤不良反应：一项前瞻性研究。
Eur J Dermatol. 2017 Jun 1;27(3):266-270. doi: 10.1684/ejd.2017.3023.
3
Development of bullous pemphigoid during nivolumab therapy.
帕博利珠单抗诱导的大疱性类天疱疮临床特征分析
Front Oncol. 2023 Mar 3;13:1095694. doi: 10.3389/fonc.2023.1095694. eCollection 2023.
4
Cutaneous manifestations associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的皮肤表现。
Front Immunol. 2023 Feb 20;14:1071983. doi: 10.3389/fimmu.2023.1071983. eCollection 2023.
5
Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.两例与免疫检查点抑制剂相关的大疱性类天疱疮罕见病例。
BMJ Case Rep. 2022 Dec 7;15(12):e253059. doi: 10.1136/bcr-2022-253059.
6
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.
7
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.接受免疫检查点抑制剂治疗的患者及银屑病患者中的大疱性类天疱疮——聚焦于临床和组织病理学变异
Dermatopathology (Basel). 2022 Mar 18;9(1):60-81. doi: 10.3390/dermatopathology9010010.
8
A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.抗PD-1治疗诱发并与不明原因神经系统疾病相关的大疱性类天疱疮的迟发性皮肤表现
Case Rep Oncol. 2021 Jun 15;14(2):861-867. doi: 10.1159/000514806. eCollection 2021 May-Aug.
9
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.癌症免疫治疗学会（SITC）免疫检查点抑制剂相关不良反应临床实践指南。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
10
Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.免疫检查点抑制剂的皮肤毒性：皮肤科医生的作用。
Yale J Biol Med. 2020 Mar 27;93(1):123-132. eCollection 2020 Mar.
纳武单抗治疗期间大疱性类天疱疮的发生
JAAD Case Rep. 2016 Dec 3;2(6):442-444. doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.
4
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.抗CTLA-4抗体伊匹木单抗治疗既往接受过抗PD-1治疗的转移性黑色素瘤患者的疗效和毒性
Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28.
5
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.大疱性类天疱疮是一种自身抗体介导的疾病，是接受抗程序性细胞死亡蛋白1抗体治疗的患者中出现的一种新型免疫相关不良事件。
Melanoma Res. 2016 Aug;26(4):413-6. doi: 10.1097/CMR.0000000000000260.
6
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.靶向 PD-1 和 PD-L1 的免疫检查点抑制剂相关的自身免疫性大疱性皮肤病。
Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.
7
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.抗程序性细胞死亡（PD）-1 治疗转移性黑色素瘤患者的皮肤不良事件（AE）：单机构队列。
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. Epub 2016 Jan 12.
8
Ipilimumab in patients with cancer and the management of dermatologic adverse events.依匹单抗在癌症患者中的应用及皮肤不良反应的管理。
J Am Acad Dermatol. 2014 Jul;71(1):161-9. doi: 10.1016/j.jaad.2014.02.035. Epub 2014 Apr 24.
9
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
10
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.